Ono Venture Investment, Inc.
Corporate VCSouth San Francisco · Seed–Series B · 6 people tracked
Investment thesis
Ono Venture Investment invests in early-stage startups to access innovative technologies and novel therapeutic drug targets, emphasizing collaboration with young companies. Its activity centers on the life sciences and biotech space, backing therapeutics developers and related platforms, and it participates in follow-on rounds to support portfolio companies as they advance.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 11 of 12 portfolio companiesBiotech ×11Medical Devices ×6AI & Machine Learning ×3Deep Tech ×3Healthtech ×3Digital Health ×2Longevity ×2
HQs:United States×5
Investments · 12 tracked
founders shown can be your intro path
Harness Therapeutics develops first-in-class drug candidates for neurodegenerative diseases such as Parkinson's and Huntington's disease, using its MISBA platform.
AI & Machine LearningBiotechHealthtechLongevityMedical Devices
Jan Thirkettle(CEO Director)
Co-investorsEpidarex CapitalDementia Discovery FundSV Health Investors
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioRA CapitalDementia Discovery FundLightstone VenturesDCVC (Data Collective)
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)
BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in
Co-investorsARCH Venture PartnersIllumina VenturesTCG CrossoverThird Rock Ventures
Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity.
BiotechDeep Tech
Co-investorsAstellas Venture Management LLCEisai Innovation, Inc.
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsDC Investment PartnersLongwood FundMedical Excellence CapitalNovartis Venture FundSolasta VenturesAgent Capital+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundPfizer Venture InvestmentsShangBay Capital LLCSofinnova Partners+2 more
Mission BioCapital is an early-stage venture capital firm that provides capital and shared lab space to life science startups, supporting founders from initial experiments through to the clinic.
Biotech
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundPfizer Venture InvestmentsSofinnova PartnersPfizer Ventures
Photys Therapeutics is a proximity-based drug developer working on targeted protein modulation medicines using its PHICS and tPRIME platforms alongside PROTAC expertise.
BiotechLongevity
Co-investorsLongwood FundMPM BioImpact8VC
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Alicia Irurzun-Lafitte(Director)Dylan Morris(Director)
Co-investorsBold Capital PartnersCRV (Charles River Ventures)FREEFLOWGlobal BrainDigitalis VenturesDolby Family Ventures+1 more
AIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions.
BiotechHealthtech
Co-investors+ND CapitalARCH Venture PartnersFast Track InitiativeNextech InvestNovalis LifeSciencesPathway Bioventures
Portfolio news
latest coverage across their companiesArbor Biotechnologies · altss.com · Jun 3, 2026
Mozart Therapeutics · nasdaqprivatemarket.com · Jun 27, 2025
Frequently asked questions
- How many investments has Ono Venture Investment, Inc. made?
- Ono Venture Investment, Inc. has 12 tracked investments.
- What stage does Ono Venture Investment, Inc. invest at?
- Ono Venture Investment, Inc. invests at the Seed, Series A, Series B stages.
- What sectors does Ono Venture Investment, Inc. focus on?
- Ono Venture Investment, Inc. focuses on Biotech, Healthtech.
- Where is Ono Venture Investment, Inc. located?
- Ono Venture Investment, Inc. is headquartered in South San Francisco, US.
- Who does Ono Venture Investment, Inc. co-invest with?
- Ono Venture Investment, Inc. most often shares deals with ARCH Venture Partners, Longwood Fund, Novartis Venture Fund, among 31 tracked co-investors.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.